Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients


23 Nov 2019


Poster display session


Tumour Site

Breast Cancer


Wataru Goto


Annals of Oncology (2019) 30 (suppl_9): ix13-ix19. 10.1093/annonc/mdz418


W. Goto1, Y. Kamei1, C. Watanabe1, S. Kashiwagi2, K. Ikeda1, Y. Ogawa1

Author affiliations

  • 1 Breast Surgical Oncology, Osaka City General Hospital, 534-0021 - Osaka/JP
  • 2 Department Of Surgical Oncology, Osaka City University Medical School, 545-8585 - Osaka/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 41P


The importance of regulating and improving the tumor immune microenvironment is increasingly being recognized. While it has been reported that therapeutic agents for hyperlipidemia, in particular statins, can induce cancer cell growth suppression and anti-metastatic effects in breast cancer, few studies have investigated the correlation between improvement of lipid metabolism and antitumor immune response and cancer prognosis in vivo.


Except for patients with ductal carcinoma in situ, 938 breast cancer patients treated with curative surgery were examined. The correlation between serum levels of total-cholesterol and triglyceride, and clinicopathological features, including pre- and postoperative neutrophil-to-lymphocyte ratio (NLR) and tumor-infiltrating lymphocytes (TILs), and prognosis was evaluated retrospectively.


194 patients were receiving treatment for hyperlipidemia. Recurrence-free survival (RFS) and overall survival (OS) did not differ significantly between users of the drug for hyperlipidemia or non-users (p = 0.782, log-rank) (p = 0.304, log-rank). Among postmenopausal patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, who were treated for hyperlipidemia, the group with good serum lipid control had significantly better RFS (p = 0.014, log-rank). Good serum lipid control was also significantly correlated with low postoperative NLR (p = 0.024). In addition, high-TILs in resected tissues was significantly associated with preoperative serum lipid levels (p = 0.039). In the drug type, lipophilic statin users had lower recurrence rate than hydrophilic statin users (8.2 % vs 16.0 %).


Good control of serum lipid metabolism may have a relationship with improvement of tumor immune microenvironment and favorable outcome in postmenopausal HR-positive/HER2-negative breast cancer patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.